PHARMASEAL and Mayet Forge Strategic Partnership to Enhance Clinical Trials

In a significant move within the life sciences sector, PHARMASEAL, renowned for its enterprise clinical trial management solutions, has announced a strategic partnership with Mayet, a key player in vendor management software specializing in clinical trial processes. This alliance marks a pivotal step toward improving efficiency and compliance in clinical trial management and vendor oversight.

Bridging Innovative Technologies

The collaboration aims to integrate PHARMASEAL's cutting-edge Engility® trial management system with Mayet's comprehensive vendor management solution. By merging these advanced platforms, the partnership seeks to provide sponsors, Contract Research Organizations (CROs), and research sites with a seamless experience in trial execution, thereby enhancing regulatory compliance and data accuracy.

Daljit Cheema, CEO of PHARMASEAL, emphasized the importance of this integration, stating, "Together, we are enabling more integrated technologies that combine powerful solutions to improve trial management, vendor oversight, and compliance while still being able to offer choice to our customers."

Tom Lazenby, CEO of Mayet, echoed this sentiment by highlighting the benefits this partnership brings to clinical trial teams. He remarked, "The integration partnership between Mayet and PHARMASEAL gives clinical trial teams complete visibility across vendor performance and trial operations on one platform. This VMS-CTMS connection assists sponsors and CROs in tracking risks, maintaining compliance, and expediting trials without the need to switch between disparate systems."

Advantages for Early Adopters

Set to roll out in 2025, the integrated solution promises early adopters enhanced functionalities that simplify clinical trial management tasks. With joined forces, both companies are confident that the collaboration will facilitate faster, more reliable clinical trials while ensuring research teams can operate within budgetary constraints.

Upcoming Podcast Discussion

In an effort to further engage with stakeholders and elucidate on the functionalities of this partnership, a podcast titled 'Strategic Trial Management Breaking Down Silos for Better Outcomes' will be hosted by Chief Product Officer Ricky Lakhani and Mayet's Tom Lazenby. The podcast will delve into how unified systems can eliminate operational blind spots, encourage cross-functional collaboration, and promote data-driven decisions that scale clinical trial operations.

Stay tuned for more information on this exciting initiative and the accompanying podcast, which will provide invaluable insights for professionals in the clinical research space.

About PHARMASEAL

Established in 2016, PHARMASEAL International Ltd has consistently focused on creating a unified trial management platform aimed at elevating clinical trials to improve global health. The Engility® Trial Management platform, developed by a dedicated team of clinical technology experts, is designed to simplify the operational complexities associated with clinical trials, enhance productivity, and promote collaboration across organizations. Built on modern cloud architecture, the Engility platform efficiently scales to accommodate diverse trial needs. For further information, you can visit their website at pharmaseal.co.

About Mayet

Mayet is at the forefront of optimizing clinical trial operations through effective vendor management. Specializing in compliance tracking, Mayet reduces administrative burdens while fostering collaboration among stakeholders in the research community. Their adaptive technology is created to support continuous improvements in processes, offering actionable insights for data-driven outsourcing decisions in clinical research. Learn more by visiting Mayetrx.com.

This partnership is set to reshape the landscape of clinical trials, allowing organizations to navigate complexities with enhanced agility while adhering to compliance requirements effectively.